[1]
Prince GT, Cameron MC, Fathi R, Alkousakis T. Topical 5-fluorouracil in dermatologic disease. International journal of dermatology. 2018 Oct:57(10):1259-1264. doi: 10.1111/ijd.14106. Epub 2018 Jun 25
[PubMed PMID: 30187924]
[2]
Gupta AK, Weiss JS, Jorizzo JL. 5-fluorouracil 0.5% cream for multiple actinic or solar keratoses of the face and anterior scalp. Skin therapy letter. 2001 Jun:6(9):1-4
[PubMed PMID: 11550079]
Level 3 (low-level) evidence
[3]
Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, Vauthey JN, Rogers JE, Ohinata A, Pathak P, Sethi S, Phillips JK, Crane CH, Wolff RA. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014 Nov 30:5(22):11133-42
[PubMed PMID: 25373735]
[4]
Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, ESMO Guidelines Committee. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Sep:27(suppl 5):v28-v37
[PubMed PMID: 27664259]
Level 1 (high-level) evidence
[5]
Liu Y, Fu H, Zuo L. Synergistic Cytotoxicity Effect of 5-Fluorouracil and SHP2 Inhibitor Demethylincisterol A3 on Cervical Cancer Cell. Anti-cancer agents in medicinal chemistry. 2022:22(7):1313-1319. doi: 10.2174/1871520621666210708130703. Epub
[PubMed PMID: 34238199]
[6]
Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2022 Oct:33(10):992-1004. doi: 10.1016/j.annonc.2022.07.003. Epub 2022 Jul 29
[PubMed PMID: 35914638]
Level 1 (high-level) evidence
[7]
Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y, Ma J. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Mar 1:39(7):840-859. doi: 10.1200/JCO.20.03237. Epub 2021 Jan 6
[PubMed PMID: 33405943]
[8]
Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. Journal of oncology practice. 2017 Sep:13(9):621-625. doi: 10.1200/JOP.2017.024919. Epub 2017 Aug 10
[PubMed PMID: 28796558]
Level 1 (high-level) evidence
[9]
Weinstock MA, Thwin SS, Siegel JA, Marcolivio K, Means AD, Leader NF, Shaw FM, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin GP, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri JE, Robinson-Bostom L, Ringer RJ, Lew RA, Ferguson R, DiGiovanna JJ, Huang GD, Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial (VAKCC) Group. Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. JAMA dermatology. 2018 Feb 1:154(2):167-174. doi: 10.1001/jamadermatol.2017.3631. Epub
[PubMed PMID: 29299592]
Level 1 (high-level) evidence
[10]
Prince GT, Cameron MC, Fathi R, Alkousakis T. Intralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review. Journal of drugs in dermatology : JDD. 2018 Mar 1:17(3):274-280
[PubMed PMID: 29537445]
Level 1 (high-level) evidence
[11]
Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules (Basel, Switzerland). 2008 Aug 5:13(8):1551-69
[PubMed PMID: 18794772]
[12]
Ceilley RI. Mechanisms of action of topical 5-fluorouracil: review and implications for the treatment of dermatological disorders. The Journal of dermatological treatment. 2012 Apr:23(2):83-9. doi: 10.3109/09546634.2010.507704. Epub 2010 Oct 31
[PubMed PMID: 21034289]
[13]
Chen L, She X, Wang T, He L, Shigdar S, Duan W, Kong L. Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. Nanoscale. 2015 Sep 7:7(33):14080-92. doi: 10.1039/c5nr03527a. Epub
[PubMed PMID: 26242620]
[14]
Entezar-Almahdi E, Mohammadi-Samani S, Tayebi L, Farjadian F. Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer. International journal of nanomedicine. 2020:15():5445-5458. doi: 10.2147/IJN.S257700. Epub 2020 Jul 30
[PubMed PMID: 32801699]
Level 3 (low-level) evidence
[15]
Ghafouri-Fard S, Abak A, Tondro Anamag F, Shoorei H, Fattahi F, Javadinia SA, Basiri A, Taheri M. 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. Frontiers in oncology. 2021:11():658636. doi: 10.3389/fonc.2021.658636. Epub 2021 Apr 19
[PubMed PMID: 33954114]
Level 3 (low-level) evidence
[16]
Srinivas NR. Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. Drug development and industrial pharmacy. 2016:42(6):945-57. doi: 10.3109/03639045.2015.1096278. Epub 2015 Oct 15
[PubMed PMID: 26467209]
[17]
Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clinical pharmacokinetics. 1989 Apr:16(4):215-37
[PubMed PMID: 2656050]
[18]
Work Group, Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. Journal of the American Academy of Dermatology. 2018 Mar:78(3):540-559. doi: 10.1016/j.jaad.2017.10.006. Epub 2018 Jan 10
[PubMed PMID: 29331385]
[19]
Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, van Herpen CML, van Erp NP. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. The Lancet. Oncology. 2019 Apr:20(4):e200-e207. doi: 10.1016/S1470-2045(19)30145-7. Epub
[PubMed PMID: 30942181]
[20]
Ozaki Y, Imamaki H, Ikeda A, Oura M, Nakagawa S, Funakoshi T, Kataoka S, Nishikawa Y, Horimatsu T, Yonezawa A, Matsubara T, Yanagita M, Muto M, Watanabe N. Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. Cancer chemotherapy and pharmacology. 2020 Nov:86(5):693-699. doi: 10.1007/s00280-020-04158-1. Epub 2020 Oct 3
[PubMed PMID: 33011861]
Level 3 (low-level) evidence
[21]
Silverstein J, Post AL, Chien AJ, Olin R, Tsai KK, Ngo Z, Van Loon K. Multidisciplinary Management of Cancer During Pregnancy. JCO oncology practice. 2020 Sep:16(9):545-557. doi: 10.1200/OP.20.00077. Epub
[PubMed PMID: 32910882]
[22]
Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, Pentheroudakis G, ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Oct:24 Suppl 6():vi160-70. doi: 10.1093/annonc/mdt199. Epub 2013 Jun 27
[PubMed PMID: 23813932]
Level 1 (high-level) evidence
[24]
Watanabe K. Current chemotherapeutic approaches for hepatoblastoma. International journal of clinical oncology. 2013 Dec:18(6):955-61. doi: 10.1007/s10147-013-0616-8. Epub 2013 Sep 20
[PubMed PMID: 24052132]
[25]
Casanova M, Bisogno G, Gandola L, Cecchetto G, Di Cataldo A, Basso E, Indolfi P, D'Angelo P, Favini F, Collini P, Potepan P, Ferrari A, Rare Tumors in Pediatric Age Group. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. Cancer. 2012 May 15:118(10):2718-25. doi: 10.1002/cncr.26528. Epub 2011 Sep 14
[PubMed PMID: 21918965]
[26]
Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Dec 10:37(35):3369-3376. doi: 10.1200/JCO.19.01276. Epub 2019 Sep 25
[PubMed PMID: 31553639]
[27]
Lund CM, Vistisen KK, Olsen AP, Bardal P, Schultz M, Dolin TG, Rønholt F, Johansen JS, Nielsen DL. The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO). British journal of cancer. 2021 Jun:124(12):1949-1958. doi: 10.1038/s41416-021-01367-0. Epub 2021 Apr 7
[PubMed PMID: 33828260]
Level 1 (high-level) evidence
[28]
Kadoyama K, Miki I, Tamura T, Brown JB, Sakaeda T, Okuno Y. Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. International journal of medical sciences. 2012:9(1):33-9
[PubMed PMID: 22211087]
[29]
Shakhbazova A, Marsch AF. Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature. Dermatology online journal. 2019 Nov 15:25(11):. pii: 13030/qt3nw0p7hn. Epub 2019 Nov 15
[PubMed PMID: 32045142]
[30]
Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, Herrmann J, Lerman A, Grothey A. 5-fluorouracil and cardiotoxicity: a review. Therapeutic advances in medical oncology. 2018:10():1758835918780140. doi: 10.1177/1758835918780140. Epub 2018 Jun 18
[PubMed PMID: 29977352]
Level 3 (low-level) evidence
[31]
Ihoriya H, Yamamoto H, Yamada T, Tsukahara K, Inoue K, Yumoto T, Naito H, Nakao A. Hyperammonemic encephalopathy in a patient receiving fluorouracil/oxaliplatin chemotherapy. Clinical case reports. 2018 Apr:6(4):603-605. doi: 10.1002/ccr3.1422. Epub 2018 Feb 13
[PubMed PMID: 29636922]
Level 3 (low-level) evidence
[32]
Teraishi F, Suzuki T, Nakamoto M, Chikuba A, Nezu M, Shimamura H, Watanabe T, Matsuda T, Takiue T, Chikuba H. [A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009 May:36(5):867-9
[PubMed PMID: 19461197]
Level 3 (low-level) evidence
[33]
Yi HJ, Hong KS, Moon N, Chung SS, Lee RA, Kim KH. Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy. Annals of surgical treatment and research. 2016 Mar:90(3):179-82. doi: 10.4174/astr.2016.90.3.179. Epub 2016 Feb 26
[PubMed PMID: 26942162]
[34]
Was H, Borkowska A, Bagues A, Tu L, Liu JYH, Lu Z, Rudd JA, Nurgali K, Abalo R. Mechanisms of Chemotherapy-Induced Neurotoxicity. Frontiers in pharmacology. 2022:13():750507. doi: 10.3389/fphar.2022.750507. Epub 2022 Mar 28
[PubMed PMID: 35418856]
[35]
Jules R, Thaper A, Foster R, Ameli P, Robinson C, Pizzi M, Babi MA, Maciel CB, Busl KM, Reddy R, Roth W. 5-Fluorouracil Neurotoxicity in the Absence of Dihydropyrimidine Dehydrogenase Deficiency Case Report. The Neurohospitalist. 2022 Apr:12(2):366-370. doi: 10.1177/19418744211068913. Epub 2022 Jan 3
[PubMed PMID: 35419161]
Level 3 (low-level) evidence
[36]
Jose N, Joel A, Selvakumar RJ, Ramireddy J, John AO, Georgy JT, Singh A, Ram TS. Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series. Journal of the Egyptian National Cancer Institute. 2022 May 23:34(1):22. doi: 10.1186/s43046-022-00117-4. Epub 2022 May 23
[PubMed PMID: 35599280]
Level 2 (mid-level) evidence
[37]
Qiao J, Fang H. Hand-foot syndrome related to chemotherapy. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2012 Oct 16:184(15):E818. doi: 10.1503/cmaj.111309. Epub 2012 Apr 16
[PubMed PMID: 22508979]
Level 2 (mid-level) evidence
[38]
Riley P, Glenny AM, Worthington HV, Littlewood A, Clarkson JE, McCabe MG. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. The Cochrane database of systematic reviews. 2015 Dec 23:2015(12):CD011552. doi: 10.1002/14651858.CD011552.pub2. Epub 2015 Dec 23
[PubMed PMID: 26695736]
Level 1 (high-level) evidence
[39]
Tayag JCS, Ishii T, Kokuba S, Hirata T, Shiohira H, Nakamura K. Changes in Pharmacodynamic Parameters during Co-administration of 5-FU with Warfarin: A Retrospective Case Series. Biological & pharmaceutical bulletin. 2022:45(8):1101-1105. doi: 10.1248/bpb.b22-00129. Epub
[PubMed PMID: 35908892]
Level 2 (mid-level) evidence
[40]
Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer chemotherapy and pharmacology. 2016 Sep:78(3):447-64. doi: 10.1007/s00280-016-3054-2. Epub 2016 May 23
[PubMed PMID: 27217046]
[41]
Yoshida Y, Ogura K, Hiratsuka A, Aisu N, Yamada T, Kojima D, Tanimura S, Ogata K, Hara S, Mogi A, Takamatsu Y, Tamura K, Mishima H, Yamashita Y. 5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method. Anticancer research. 2015 Sep:35(9):4881-7
[PubMed PMID: 26254383]
[43]
Traynor K. FDA approves therapy to treat overdose of fluorouracil, capecitabine. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2016 Feb 1:73(3):100, 102. doi: 10.2146/news160010. Epub
[PubMed PMID: 26796900]
[44]
Ma WW, Saif MW, El-Rayes BF, Fakih MG, Cartwright TH, Posey JA, King TR, von Borstel RW, Bamat MK. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017 Jan 1:123(2):345-356. doi: 10.1002/cncr.30321. Epub 2016 Sep 13
[PubMed PMID: 27622829]
[45]
Korgavkar K, Lee KC, Weinstock MA, Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group. Effect of Topical Fluorouracil Cream on Photodamage: Secondary Analysis of a Randomized Clinical Trial. JAMA dermatology. 2017 Nov 1:153(11):1142-1146. doi: 10.1001/jamadermatol.2017.2578. Epub
[PubMed PMID: 28877312]
Level 1 (high-level) evidence
[46]
Metterle L, Nelson C, Patel N. Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review. Journal of the American Academy of Dermatology. 2016 Mar:74(3):552-7. doi: 10.1016/j.jaad.2015.09.040. Epub 2015 Nov 11
[PubMed PMID: 26577512]
[47]
Srivastava S, Patil A, Prakash C, Kumari H. Comparison of Intralesional Triamcinolone Acetonide, 5-Fluorouracil, and Their Combination in Treatment of Keloids. World journal of plastic surgery. 2018 May:7(2):212-219
[PubMed PMID: 30083505]